BERLIN, GERMANY (UroToday.com) - EAU 2007 - A poster session on "Minimally Invasive and Other Treatment Strategies in Localized Prostate Cancer" EAU on Friday March 23, 2007.

Dr. Ismail, Guildford presented "Salvage Cryotherapy for Recurrent Prostate Cancer, the UK Experience". In the study, 100 patients underwent salvage cryoablation of the prostate between 2000-2005. Mean patient age was 67 years and mean follow-up was 27.5 months. All men had biopsy documented recurrence of CaP and were risk stratified based upon PSA, Gleason score and clinical stage. No patient mortality occurred and 61% received androgen deprivation therapy prior to cryoablation. The 5-year biochemical recurrence free survival was 73% for low-risk patient, 45% for intermediate-risk men and 11% for high-risk patients. The reported complications included incontinence (13%), erectile dysfunction (86%), LUTS (16%), prolonged perineal pain (4%), urinary retention (2%) and rectovesical fistula (1%). The authors feel that these data suggest that cryotherapy is safe and effective treatment for CaP recurrence. Patient selection clearly impacts outcome and the data does not clearly support benefit in high-risk patients.

EAU 2007 - Abstract#705  -(Salvage Cryotherapy for Recurrent Prostate Cancer. The UK Experience)

Dr. Murat, Lyon reported on outcomes in 463 men treated for localized CaP with a first generation HIFU device. Treatment was using the Ablatherm Maxis HIFU device. Mean patient age was 69 years with clinical cT1-2 CaP, PSA less than 15ng/ml and Gleason score less than 7. Mean PSA was 7.6 and Gleason less than 6 in 299 and =7 in 164 patients. With a mean follow-up of 23 months, the 3-month control biopsies were negative in 85% of cases. In 77% a PSA nadir was achieved at 4 months. The 4-year actuarial overall CaP-free survival rate was 64%. The rate inversely correlated with clinical and pathological parameters. Urinary incontinence and bladder outlet obstruction occurred in 8% and 8% of patients, respectively. The authors conclude that this treatment modality is appropriate for patients with localized CaP who are not candidates for surgery. The oncological outcomes appear inferior to rates reported for radiotherapy and surgery.

EAU 2007 - Abstract#711  - Prostate Cancer Control in 463 Patients Treated with the First Generation HIFU Machine

EAU 2007 Conference Coverage on UroToday.com

Written by Christopher P. Evans, MD, a Contributing Editor with UroToday.

Please log-in or register in order to submit comments.

Powered by AkoComment!